Comparative Study of BAY86-5300 With a Flexible Extended Regimen for Dysmenorrhea

A Multi-center, Randomized, Open-label, Active-controlled, Parallel-group Comparative Study to Assess Efficacy and Safety of a Flexible Extended Regimen of BAY 86-5300 (0.02 mg Ethinylestradiol [β-CDC] and 3 mg Drospirenone) Compared to the 28-day (24 + 4-day) Regimen of BAY 86-5300 in the Treatment of Dysmenorrhea for 24 Weeks

The is a multi-center, randomized, open-label, active-controlled, parallel-group comparative study (24-week treatment period).

The objective of this study is to prove the superiority of BAY 86-5300 with flexible extended regimen for treatment of dysmenorrhea to BAY 86-5300 with 28-day cyclic regimen in terms of primary efficacy variable, number of days with dysmenorrheic pain over 140 days of evaluation period.

In addition, the long-term safety of the flexible extended regimen of BAY86-5300 in patients treated for one year will be investigated.

Study Overview

• Status: Completed
• Conditions: Dysmenorrhea
• Intervention / Treatment: Drug: EE20/DRSP(BAY86-5300)

• Study Type: Interventional
• Enrollment (Actual): 216
• Phase: Phase 3

Contacts and Locations

Study Locations

• Japan
  • Osaka, Japan, 530-0013
  • Osaka, Japan, 542-0086
  • Chiba
    • Matsudo, Chiba, Japan, 270-2267
  • Tokyo
    • Hachioji, Tokyo, Japan, 192-0046
    • Minato, Tokyo, Japan, 108-0071
    • Setagaya-ku, Tokyo, Japan, 157-0066
    • Suginami-ku, Tokyo, Japan, 167-0051
    • Toshima-ku, Tokyo, Japan, 171-0021

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria: - Dysmenorrhea patients with a total dysmenorrhea score (sum of the two sub-scores: severity of dysmenorrhea and use of analgesics) of at least 3 points in each of the last two menstruations before randomization (baseline observation phase)

• Patients with dysmenorrheic pain during the 2 baseline cycles before randomization. Dysmenorrheic pain means any spasmodic pelvic pain or lower abdominal pain with possible radiation towards back or thighs recorded in the Patient Diary in correspondence with a withdrawal and/or menstrual bleeding episode. Pain could start up to 2 days before the onset of the bleeding episode the bleeding and terminates on the last day of bleeding of before
• Patients having the regular cyclic menstrual period (25 to 38 days) in the latest two menses before randomization (baseline observation phase)
• Willingness to use a barrier method (i.e., non-hormonal method) for contraception during the study. Acceptable methods of contraception include (i) condoms (male or female) with or without a spermicidal agent; (ii) diaphragm or cervical cap with spermicide; (iii) intra-uterine device.

Exclusion Criteria: - Patients who have organic diseases of which surgical treatment is prioritized by the investigator

• Patients aged 40 years or older with ovarian chocolate cysts being more than 10 cm in size of the longest diameters
• Patients with ovarian chocolate cysts having solid part in the cyst
• Patients for whom YAZ Combination Tablet is contraindicated (according to Japanese Labeling)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: EE20/DRSP(BAY86-5300)-flexibel extended regimen; One tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day with flexible extended regimen (24-day to 120-day active tablet intake followed by 4-day tablet free interval)	Drug: EE20/DRSP(BAY86-5300); One tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day
Active Comparator: EE20/DRSP(BAY86-5300)-28 days cyclic regimen; One tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day with 28-day cyclic regimen (24-day active tablet intake followed by 4-day placebo tablet intake)	Drug: EE20/DRSP(BAY86-5300); One tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of days with dysmenorrheic pain over 140 days of evaluation period	Number of days with dysmenorrheic pain is determined based on daily record of Patient Diary.	Evaluation period which starts on 25th day after start of treatment and lasts for 140 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Dysmenorrhea score from baseline to period of withdrawal bleeding	Dysmenorrhea score is a sum of the two sub-scores, severity of dysmenorrhea and use of analgesics, recorded by the participant at every visit	Baseline period (8 weeks before start of treatment) and evaluation period which starts on 25th day after start of treatment and lasts for 140 days
Change of severity of pain Description	The severity of pain is measured by the Visual Analogue Scale (VAS), recorded by the participant at any visit.	Baseline period (8 weeks before start of treatment) and evaluation period which starts on 25th day after start of treatment and lasts for 140 days
Number of days with at least moderate dysmenorrheic pain over 140 days of evaluation period	Number of days with at least moderate dysmenorrheic pain is determined based on daily record of Patient Diary.	Evaluation period which starts on 25th day after start of treatment and lasts for 140 days
Number of days with rescue medicine used for relief of dysmenorrhea or pelvic pain over 140 days of evaluation period	Number of days with rescue medicine is determined based on daily record of Patient Diary.	Evaluation period which starts on 25th day after start of treatment and lasts for 140 days
Number of days with interference of dysmenorrheic pain with daily activity over 140 days of evaluation period	Number of days with interference of dysmenorrheic pain with daily activity is determined based on daily record of Patient Diary	Evaluation period which starts on 25th day after start of treatment and lasts for 140 days
Endometrial thickness	Endometrial thickness is the thickest value (mm) of endometrium determined by transvaginal ultrasonography.	24 weeks after taking the initial study medication
Number of days with bleeding and spotting over treatment phase	Number of days with spotting/bleeding is determined based on daily record of Patient Diary.	Up to 24 weeks

Collaborators and Investigators

• Sponsor: Bayer

Publications and helpful links

General Publications

• Momoeda M, Akiyama S, Yamamoto S, Kondo M, Fukai T. Burden of Menstrual Pain Measured by Heatmap Visualization of Daily Patient-Reported Data in Japanese Patients Treated with Ethinylestradiol/Drospirenone: A Randomized Controlled Study. Int J Womens Health. 2020 Mar 10;12:175-185. doi: 10.2147/IJWH.S242864. eCollection 2020.

Study record dates

Study Major Dates

• Study Start: July 1, 2013
• Primary Completion (Actual): January 1, 2015
• Study Completion (Actual): August 1, 2015

Study Registration Dates

• First Submitted: July 2, 2013
• First Submitted That Met QC Criteria: July 2, 2013
• First Posted (Estimate): July 8, 2013

Study Record Updates

• Last Update Posted (Estimate): September 9, 2015
• Last Update Submitted That Met QC Criteria: September 8, 2015
• Last Verified: September 1, 2015

More Information

Terms related to this study

• Keywords: Dysmenorrhea; Japanese patients; Drospirenone; YAZ; Flexible regimen; Ethinylestradiol Betadex
• Additional Relevant MeSH Terms: Pathologic Processes; Pain; Neurologic Manifestations; Menstruation Disturbances; Pelvic Pain; Dysmenorrhea
• Other Study ID Numbers: 16114